<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DD21B8FC-26A6-4A3A-9A23-207B6667CB41"><gtr:id>DD21B8FC-26A6-4A3A-9A23-207B6667CB41</gtr:id><gtr:name>University of Pittsburgh</gtr:name><gtr:address><gtr:line1>University of Pittsburgh</gtr:line1><gtr:line4>Pittsburgh</gtr:line4><gtr:line5>Pennsylvania</gtr:line5><gtr:postCode>PA 15260</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D7900CE2-A312-427D-AB82-2F88341AE2B5"><gtr:id>D7900CE2-A312-427D-AB82-2F88341AE2B5</gtr:id><gtr:name>SomaLogic</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Sir William Dunn Sch of Pathology</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DD21B8FC-26A6-4A3A-9A23-207B6667CB41"><gtr:id>DD21B8FC-26A6-4A3A-9A23-207B6667CB41</gtr:id><gtr:name>University of Pittsburgh</gtr:name><gtr:address><gtr:line1>University of Pittsburgh</gtr:line1><gtr:line4>Pittsburgh</gtr:line4><gtr:line5>Pennsylvania</gtr:line5><gtr:postCode>PA 15260</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D7900CE2-A312-427D-AB82-2F88341AE2B5"><gtr:id>D7900CE2-A312-427D-AB82-2F88341AE2B5</gtr:id><gtr:name>SomaLogic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/04C1679B-7BCB-4AFB-B346-BE79DC581A0A"><gtr:id>04C1679B-7BCB-4AFB-B346-BE79DC581A0A</gtr:id><gtr:firstName>William</gtr:firstName><gtr:otherNames>Siward</gtr:otherNames><gtr:surname>James</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0401610"><gtr:id>2EDBB390-6D0C-4321-BAE3-EBB0BC1A1E4C</gtr:id><gtr:title>Functional mapping of gp120 binding sites of neutralizing aptamers</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0401610</gtr:grantReference><gtr:abstractText>Since 1981, when AIDS was first described, the disease has claimed in excess of 20 million lives and now affects most communities worldwide. In the developing world, where 85% of people with HIV live, the life expectancy and economic potential of many countries is being substantially reduced by AIDS. In spite of the successful development of effective antiviral therapy in the 1990s, the epidemic continues to grow beyond our capacity to counter it. While much of the solution to this problem arguably lies in the spheres of public health and international politics, a sustainable and sufficient approach will inevitably require the development of new classes of drug and effective vaccines. A key target for antiviral immune responses and also for potential antivirals is the molecular process of cellular attachment and penetration by HIV-1 virions. We have developed a set of reagents and techniques around anti-viral aptamers which we believe form the basis for powerfully investigating this target in the virus life cycle. This proposal aims to exploit aptamers not only to satisfy our scientific curiosity about the biology of HIV but provide realistic leads into vaccine and drug development.</gtr:abstractText><gtr:technicalSummary>We have recently described a set of aptamers that, in contrast to most antibodies, potently neutralize clinically relevant isolates of HIV from all clades. This breakthrough promises to uncover novel approaches to therapy and a more detailed understanding of HIV-receptor interaction.

As part of a larger programme of inter-related projects designed to exploit this development, here we propose a project to define the binding site(s) of the neutralizing aptamers by a combination of mutagenesis and competition with defined ligands.

In one part of the project, in collaboration with Dennis Burton and Don Mosier, Scripps, we shall study the binding of more than 3 dozen distinct, neutralizing aptamers to an extensive panel of defined mutations in gp120. The Burton panel comprises alanine-substitutions of key residues known or believed to be important in interactions with gp120?s natural receptors and antibodies. The Mosier collection includes in vitro-selected tropism variants of BaL and Ada. The results will define both contact positions between aptamer and gp120, that might reveal important potential therapeutic targets, and sites determining long-range interactions within the protein.

In the second part, we shall undertake a competition study, using recombinant gp120, firstly between pair wise combinations of aptamers (in order to determine the number of distinct ?aptatopes? on the surface of gp120), secondly with epitope-mapped antibodies, and thirdly with natural receptors, such as heparin sulphate, CCR5 (sulpho-tyr N-terminus) and CD4.</gtr:technicalSummary><gtr:fund><gtr:end>2009-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>230000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leeds</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biochemistry and Microbiology Leeds</gtr:department><gtr:description>Collaborative aptamer discovery</gtr:description><gtr:id>7B8925FA-9E4A-421C-91EA-8C05D51EB6E3</gtr:id><gtr:impact>Research paper describing isolation and characterization of HSV-2-neutralizing patamers in preparation.</gtr:impact><gtr:outcomeId>73AED5E0B53-1</gtr:outcomeId><gtr:partnerContribution>We have been able to out-source the in vitro selection (SELEX) of new aptamers to the BBSRC-funded facility run by Professor Stockley. This has proved cost-effective and has generated high quality hits.</gtr:partnerContribution><gtr:piContribution>We have provided the scientific rationale, the recombinant protein, the preferred chemistry and the aptamer evaluation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>SomaLogic</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Evaluation of antiviral Somamers</gtr:description><gtr:id>D4E0950C-22F9-4ACF-9D2B-422D2899BD69</gtr:id><gtr:impact>No outputs as yet.

Disciplines: Nucleic acid chemistry; virology, stem cell biology, immunology</gtr:impact><gtr:outcomeId>58c132db9163c8.00050860-1</gtr:outcomeId><gtr:partnerContribution>SomaLogic undertake the in vitro evolution of proprietary slow off-rate aptamers</gtr:partnerContribution><gtr:piContribution>We are evaluating the potential neutralizing potential of slow off-rate aptamers isolated by SomaLogic against emerging viruses.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Pittsburgh</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>NIH Aptamer Microbicide Program</gtr:description><gtr:id>90AEF2F9-2236-4EF1-9025-79ED03A064A0</gtr:id><gtr:impact>Major output so far has been to secure a substantial NIH U01 program grant. We have characterized the range of nuclease environments found in human rectal and vaginal lavages, the sites of cleavage within semi-protected nuclecic acid aptamers, and the necessary stabilizing modification. We have also isolated neutralizing aptamers to HSV-2, a second sexually-transmitted virus. We plan to submit 3 papers describing this work over the next year.</gtr:impact><gtr:outcomeId>01BCA2A738A-1</gtr:outcomeId><gtr:piContribution>The initial MRC-funded work in my lab on g120 aptamers produced optimized lead structures that were the basis of a successful bid for an NIH U01 program to develop aptamers as potential microbicides. The partnership is with Prof Ian McGowan, then of ULCL, now U Pittsburgh, who elads the consortium and is the ID clinican, and Dr Brian Sproat, at IDT, Leuven, who is the commercial aprtner, and leads the synthetic chemistry project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>5000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Discovery Award</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Parkinson's UK</gtr:fundingOrg><gtr:id>8BD8EE60-6233-400F-B93F-234450C76673</gtr:id><gtr:outcomeId>37F95B9C7790</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>The aptamers resulting from the MRC award, subsequently reduced to practice under an NIH Programme award to me were protected by a patent filing the assignment of which was transferred from the University of Oxford to CSIR, South Africa, to enable them to pursue clinical development with a view to producing a broadly-protective microbicide. Professor Makobetsa Khati, who worked on the project in my laboratory, has been pursuing the implementation of this programme as the head of the Emerging Health Technologies platform at CSIR and has just been appointed Executive Director of the Research Chairs and Centres of Excellence (RCCE) directorate at the National Research Foundation (NRF) in South Africa, partly in recognition of this work.</gtr:description><gtr:id>756A7104-D29F-416E-9EAF-AFD299638668</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>56d9bbf87fa384.21137541</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>neutralizing anti-HIV aptamer</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.csir.co.za/biosciences/Emerging_Health_Technologies/</gtr:url><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A core facility to enable researchers from multiple laboratories throughout Oxford to udnertake pilot experiemtns to evaluate the use of stem cell technology in their area of scientific interest.</gtr:description><gtr:id>67BBB014-9727-4E5D-BB69-C871FDCAAE7A</gtr:id><gtr:impact>This has enabled us to secure philanthropic funds from the Parkinson's Disease Society and James Martin to expand and develop the support for stem cell technology in Oxford.</gtr:impact><gtr:outcomeId>7A5985752EF</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Oxford Stem Cell Facility</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A reproducible source of authentic human monocytes and macrophages that is amenable to genetic manipualtion.</gtr:description><gtr:id>B155CF43-BCDD-4C46-97C5-A39DF10F534D</gtr:id><gtr:impact>The ability of scientists interested in pathogen interactions with macrophages to conduct high quality forward genetics under physiologically relevant conditions, for the first time.</gtr:impact><gtr:outcomeId>DF2CF0701A1</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Human embryonic stem cell-derived monocytes and macrophages</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>349DB715-6DF0-40F2-8975-7A73767E5566</gtr:id><gtr:title>An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2356a716118baed34a34e1ca28b7263f"><gtr:id>2356a716118baed34a34e1ca28b7263f</gtr:id><gtr:otherNames>Cohen C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>ACAF01999E0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3233DB8-C4F3-4853-B9BF-13499A233EE5</gtr:id><gtr:title>Protection of HIV neutralizing aptamers against rectal and vaginal nucleases: implications for RNA-based therapeutics.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4f0074280f688071dc251da2ed692bc"><gtr:id>f4f0074280f688071dc251da2ed692bc</gtr:id><gtr:otherNames>Moore MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>SeSzESrWLEC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35AB1817-952C-4478-A9D0-532426F4FC6E</gtr:id><gtr:title>Generation of neutralizing aptamers against herpes simplex virus type 2: potential components of multivalent microbicides.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4f0074280f688071dc251da2ed692bc"><gtr:id>f4f0074280f688071dc251da2ed692bc</gtr:id><gtr:otherNames>Moore MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>Kg1Y6woC5c2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FA78238-1582-4959-AF6F-2931010640E3</gtr:id><gtr:title>Proteomic-based identification of CD4-interacting proteins in human primary macrophages.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cdccaaa61cf19af81beea4dc3806fba"><gtr:id>6cdccaaa61cf19af81beea4dc3806fba</gtr:id><gtr:otherNames>Raposo RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>iARu4rCvnm8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86884F11-A67B-4534-A9C4-DB69C176D869</gtr:id><gtr:title>HIV entry in macrophages is dependent on intact lipid rafts.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a2f1a9b626406cb0e59633f10d0c7c7"><gtr:id>2a2f1a9b626406cb0e59633f10d0c7c7</gtr:id><gtr:otherNames>Carter GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>B6C8D4BE15A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FF0D0C3-6050-4D53-94C9-FB15D6A2E593</gtr:id><gtr:title>Homogeneous monocytes and macrophages from human embryonic stem cells following coculture-free differentiation in M-CSF and IL-3.</gtr:title><gtr:parentPublicationTitle>Experimental hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4ac7baa2c1959147aa3aafc8049f58e"><gtr:id>d4ac7baa2c1959147aa3aafc8049f58e</gtr:id><gtr:otherNames>Karlsson KR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0301-472X</gtr:issn><gtr:outcomeId>DFF2BC818EC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9828CA57-F5D2-48A2-9F93-BFB1143CE448</gtr:id><gtr:title>HIV-1 infects macrophages by exploiting an endocytic route dependent on dynamin, Rac1 and Pak1.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a2f1a9b626406cb0e59633f10d0c7c7"><gtr:id>2a2f1a9b626406cb0e59633f10d0c7c7</gtr:id><gtr:otherNames>Carter GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>fg9Cp6yk3Y6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>712C245F-275A-4052-A56D-E2E058C90E24</gtr:id><gtr:title>Protein kinase C and NF-?B-dependent CD4 downregulation in macrophages induced by T cell-derived soluble factors: consequences for HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cdccaaa61cf19af81beea4dc3806fba"><gtr:id>6cdccaaa61cf19af81beea4dc3806fba</gtr:id><gtr:otherNames>Raposo RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>MEKPgUbPrkf</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0401610</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>